PubMed
Alpha-MSH tripeptide analogs reduce inflammation
Luger TA, Brzoska T. Ann N Y Acad Sci. 2004
Compare
KPV vs Thymosin Alpha-1
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
KPV
54 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
210
Mood
210
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.2–3 mg
0.2–0.4 mg
116
0.4–0.6 mg
89
0.6–1 mg
3
1–2 mg
1
2–3 mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 60 days · Based on 43 repeat reporters
Thymosin Alpha-1
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
7
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Inflammation
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.4–2 mg
0.4–0.6 mg
4
1–2 mg
3
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Sources (12)
Published sources linked on the KPV and Thymosin Alpha-1 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
KPV tripeptide exerts anti-inflammatory effects in intestinal epithelial cells
Brzoska T, Luger TA, Maaser C, et al. Dig Dis Sci. 2010
- Wiki study page →Source
PubMed
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
Kannengiesser K, Maaser C, Heidemann J, et al. Inflamm Bowel Dis. 2008
- Wiki study page →Source
PubMed
alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells
Elliott RJ, Szabo M, Wagner MJ, et al. J Invest Dermatol. 2004
- Wiki study page →Source
ClinicalTrials.gov
KPV peptide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
The neuroimmunomodulatory peptide alpha-MSH
Ichiyama T, Sato S, Okada K, et al. Annals of the New York Academy of Sciences. 2000
- Wiki study page →Source
PubMed
Thymosin alpha 1: A comprehensive review of the literature
Romani L, Moretti S, Fallarino F, et al. Expert Opin Biol Ther. 2020
- Wiki study page →Source
PubMed
Thymosin alpha 1: past clinical experience and future promise
Tuthill C, Rios I, McBeath R. Ann N Y Acad Sci. 2010
- Wiki study page →Source
PubMed
Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers
Garaci E, Pica F, Serafino A, et al. Ann N Y Acad Sci. 2014
- Wiki study page →Source
ClinicalTrials.gov
Thymosin alpha-1 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach
Naylor PH, Mutchnick MG. Journal of viral hepatitis. 2018
- Wiki study page →Source
PubMed
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
Al-Mahtab M, Bazinet M, Vaillant A. PloS one. 2016